152 related articles for article (PubMed ID: 24403249)
1. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
Craveiro V; Yang-Hartwich Y; Holmberg JC; Joo WD; Sumi NJ; Pizzonia J; Griffin B; Gill SK; Silasi DA; Azodi M; Rutherford T; Alvero AB; Mor G
Cancer Med; 2013 Dec; 2(6):751-62. PubMed ID: 24403249
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer.
Chen H; Lee LJ; Vincent KM; Xu Z; Liu J; Zhang G; Nakevska Z; Smith D; Lee CH; Postovit LM; Fu Y
Oncogene; 2024 May; 43(22):1688-1700. PubMed ID: 38594503
[TBL] [Abstract][Full Text] [Related]
3. The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells.
Kajiyama H; Shibata K; Ino K; Mizutani S; Nawa A; Kikkawa F
Cancer Sci; 2010 Feb; 101(2):347-54. PubMed ID: 19917055
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells.
Jia L; Zhang S; Ye Y; Li X; Mercado-Uribe I; Bast RC; Liu J
Cancer Lett; 2012 Dec; 326(2):176-82. PubMed ID: 22902993
[TBL] [Abstract][Full Text] [Related]
5. Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer.
Standing D; Dandawate P; Gunewardena S; Covarrubias-Zambrano O; Roby KF; Khabele D; Jewell A; Tawfik O; Bossmann SH; Godwin AK; Weir SJ; Jensen RA; Anant S
Cell Death Dis; 2024 May; 15(5):362. PubMed ID: 38796478
[TBL] [Abstract][Full Text] [Related]
6. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
Liu H; Xiao F; Serebriiskii IG; O'Brien SW; Maglaty MA; Astsaturov I; Litwin S; Martin LP; Proia DA; Golemis EA; Connolly DC
Clin Cancer Res; 2013 Sep; 19(18):5053-67. PubMed ID: 23900136
[TBL] [Abstract][Full Text] [Related]
7. Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer.
Cai Q; Zhao Z; Antalis C; Yan L; Del Priore G; Hamed AH; Stehman FB; Schilder JM; Xu Y
FASEB J; 2012 Aug; 26(8):3306-20. PubMed ID: 22767227
[TBL] [Abstract][Full Text] [Related]
8. Metronomic and single high-dose paclitaxel treatments produce distinct heterogenous chemoresistant cancer cell populations.
Mejia Peña C; Skipper TA; Hsu J; Schechter I; Ghosh D; Dawson MR
Sci Rep; 2023 Nov; 13(1):19232. PubMed ID: 37932310
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model.
Zhou J; Zhang H; Gu P; Margolick JB; Yin D; Zhang Y
Breast Cancer Res Treat; 2009 May; 115(2):269-77. PubMed ID: 18506619
[TBL] [Abstract][Full Text] [Related]
10. Targeting the tumour microenvironment in ovarian cancer.
Hansen JM; Coleman RL; Sood AK
Eur J Cancer; 2016 Mar; 56():131-143. PubMed ID: 26849037
[TBL] [Abstract][Full Text] [Related]
11. Role of CD44 and CD24 Expression on 2-years Disease Free Survival in Patients with Advanced Epithelial Ovarian Carcinoma.
Feharsal Y; Andrijono A; Singoprawiro CS; Lisnawati L; Pakasi TA; Putra AD; Kusuma F; Anggraeni TD; Erlina E; Sarwanti S; Mardhiyah T
Asian Pac J Cancer Prev; 2024 Feb; 25(2):513-519. PubMed ID: 38415537
[TBL] [Abstract][Full Text] [Related]
12. Human Omental Mature Adipocytes used as Paclitaxel Reservoir for Cell-Based Therapy in Ovarian Cancer.
Andele PK; Palazzolo S; Corona G; Caligiuri I; Kamensek U; Cemazar M; Canzonieri V; Rizzolio F
Adv Healthc Mater; 2024 Jun; 13(15):e2304206. PubMed ID: 38334216
[TBL] [Abstract][Full Text] [Related]
13. Mutation characteristics and molecular evolution of ovarian metastasis from gastric cancer and potential biomarkers for paclitaxel treatment.
Yu P; Hu C; Ding G; Shi X; Xu J; Cao Y; Chen X; Wu W; Xu Q; Fang J; Huang X; Yuan S; Chen H; Wang Z; Huang L; Pang F; Du Y; Cheng X
Nat Commun; 2024 May; 15(1):3771. PubMed ID: 38704377
[TBL] [Abstract][Full Text] [Related]
14. Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice.
Hensley HH; Roder NA; O'Brien SW; Bickel LE; Xiao F; Litwin S; Connolly DC
Neoplasia; 2012 Jun; 14(6):451-62. PubMed ID: 22787427
[TBL] [Abstract][Full Text] [Related]
15. Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype.
Alvero AB; Montagna MK; Craveiro V; Liu L; Mor G
Am J Reprod Immunol; 2012 Mar; 67(3):256-65. PubMed ID: 21917055
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on New Hallmarks of Drug-Resistance towards Personalized Care for Epithelial Ovarian Cancer.
Frezzini S; Lonardi S
Cells; 2024 Mar; 13(7):. PubMed ID: 38607050
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype.
Berry NB; Bapat SA
J Ovarian Res; 2008 Nov; 1():8. PubMed ID: 19025622
[TBL] [Abstract][Full Text] [Related]
18. Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies.
Wu Z; Lu J; Loo A; Ho N; Nguyen D; Cheng PY; Mohammed AI; Cirillo N
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542115
[TBL] [Abstract][Full Text] [Related]
19. Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations.
Lee AH; Mejia Peña C; Dawson MR
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326569
[TBL] [Abstract][Full Text] [Related]
20. Author Correction: Inhibition of Drp1 orchestrates the responsiveness of breast cancer cells to paclitaxel but insignificantly relieves paclitaxel‑related ovarian damage in mice.
Alalawy AI; Sakran M; Alzuaibr FM; Alotaibi MA; El-Hefnawy ME; Hazazi AY; El-Gendy SM; Aidy EA; Effat H; Ismail DF; Hessien M
Sci Rep; 2024 Apr; 14(1):9788. PubMed ID: 38684881
[No Abstract] [Full Text] [Related]
[Next] [New Search]
